Đang chuẩn bị liên kết để tải về tài liệu:
Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triplenegative breast cancer: A systematic review and meta-analysis

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Some studies have shown that Immune checkpoint inhibitors (ICIs) have a favorable efcacy in advanced triple negative breast cancer (TNBC) patients, but the results are controversial in neoadjuvant chemotherapy (NACT) stage. The purpose of this study is to evaluate the efcacy and safety after NACT plus ICIs in early TNBC patients. |

TÀI LIỆU LIÊN QUAN

Prevalence of immune-related adverse events and anti-tumor efcacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme

Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma

Re-challenging immune checkpoint inhibitor in a patient with advanced nonsmall cell lung cancer: A case report

The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation

Questionnaire-based detection of immunerelated adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma

Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: A clinicogenomic TCGA study

Immune checkpoint inhibitors and their impact on liver enzymes and attenuation

The epigenetic immunomodulator, HBI8000, enhances the response and reverses resistance to checkpoint inhibitors